Interim Data Demonstrating Safety & Confirmed Clinical Responses of ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Ph 1b/2 Trial Announced January 11, 2025
